Black Diamond Therapeutics (BDTX) Total Non-Current Liabilities (2018 - 2020)

Black Diamond Therapeutics (BDTX) has reported Total Non-Current Liabilities for 3 consecutive years, with $21.9 million the latest figure, recorded in Q4 2020.

• For the quarter ending Q4 2020, Total Non-Current Liabilities rose 350.59% year-over-year to $21.9 million; the trailing twelve-month figure through Dec 2020 stood at $21.9 million (up 350.59% YoY), and the FY2020 full-year result was $21.9 million, up 350.59% from the prior year.
• Total Non-Current Liabilities rose to $21.9 million in Q4 2020 per BDTX's latest filing, from $19.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $21.9 million in Q4 2020 and bottomed at $2.6 million in Q4 2018.
• Historically, Total Non-Current Liabilities has averaged $10.4 million across 3 years, with a median of $6.9 million in 2020.
• The sharpest annual moves came in 2019 and 2020: Total Non-Current Liabilities soared 88.85% in 2019, then jumped 350.59% in 2020.
• Over 3 years, Total Non-Current Liabilities stood at $2.6 million in 2018, then jumped by 88.85% to $4.9 million in 2019, then surged by 350.59% to $21.9 million in 2020.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $21.9 million, $19.1 million, and $6.3 million for Q4 2020, Q3 2020, and Q2 2020 respectively.